Sun Pharma, Cipla enter licensing agreement with Takeda to market novel gastrointestinal drug in India

Sun Pharma and Cipla have entered a licensing deal with Takeda Pharmaceutical to commercialize Vonoprazan tablets in India. This novel drug, used to treat Gastroesophageal Reflux Disease (GERD) and related acid disorders, will be marketed by Sun Pharma as Voltapraz and by Cipla under their own brands.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZnMT0JL
via IFTTT